论文部分内容阅读
为了探讨非亲缘供者外周血造血干细胞移植(UD-HSCT)治疗恶性血液病的可行治疗方案和疗效,应用高分辨HLA配型(HLA-A、-B、-DR)完全相合或1个位点不合的非亲缘供者外周血造血干细胞移植治疗恶性血液病10例,预处理方案采用马利兰、环磷酰胺、阿糖胞苷、甲基环己亚硝脲和抗胸腺细胞球蛋白,以霉酚酸酯、环孢素A加短疗程的甲氨喋呤、舒莱预防移植物抗宿主病(GVHD)。结果显示,中性粒细胞回升>0.5×109/L的中位时间为13天,血小板回升>20×109/L的中位时间为17.5天;28天STR-PCR检测显示,10例均为完全供者型;急性GVHD3例(Ⅰ度1例自行缓解,Ⅲ度1例治愈,Ⅵ度1例死亡)。结论:在非亲缘供者外周血造血干细胞移植治疗恶性血液病过程中采用上述预处理方案和GVHD预防措施是可行而且有效的。
To investigate the feasibility and efficacy of non-related donor peripheral blood stem cell transplantation (UD-HSCT) for the treatment of hematologic malignancies, we applied high-resolution HLA typing (HLA-A, -B, -DR) 10 cases of non-related non-related donor peripheral blood stem cell transplantation for the treatment of hematologic malignancies, pretreatment program using Maryland, cyclophosphamide, cytarabine, methylcyclohexamide and anti-thymocyte globulin to mold Phenolic acid esters, cyclosporin A plus short course methotrexate, Shure prevent graft versus host disease (GVHD). The results showed that the median time of neutrophil recovery> 0.5 × 109 / L was 13 days and that of platelet recovery> 20 × 109 / L was 17.5 days. STR-PCR at 28 days showed that 10 cases were Complete donor type; 3 cases of acute GVHD (Ⅰ degree 1 cases of self-remission, Ⅲ degree 1 case of cure, Ⅵ degree 1 case of death). Conclusion: It is feasible and effective to adopt the above preconditioning and GVHD prophylaxis in the treatment of hematologic malignancies by unrelated donor peripheral blood stem cell transplantation.